Dienstag, 24. Mai 2016
HAL Allergy: First In-Human study peanut allergy
The study was conducted in Denmark and showed very encouraging results which support the further clinical development of the product to present a novel treatment for severe allergic patients suffering from peanut allergy.
HAL Allergy has successfully completed a Phase I trial with its novel subcutaneous immunotherapy (SCIT) product for treatment of peanut allergy. The subcutaneous immunotherapeutic drug contains peanut allergens that have been modified using proprietary technology to reduce their allergenicity. The study was a randomized, double-blind, placebo controlled study performed at the Research Center for Anaphylaxis of the Odense University Hospital in Denmark. The study population included adult subjects with a clinically confirmed peanut allergy. The results show that treatment was generally safe and well tolerated. The combined results of the secondary parameters indicate that subcutaneous administration is capable of inducing immunological changes, suggesting progression of desensitization to peanut allergens following 3-4 months of weekly dose escalation. "Peanut allergy is a serious problem to modern society. With our current achievement, we are taking a promising step towards the treatment of peanut allergy, which is based on our experience in developing allergy therapies since 1959." says Dr. Harry Flore, Chief Executive Officer of HAL Allergy.
About Peanut Allergy
Peanut allergy is an immunoglobulin E (IgE) mediated hypersensitivity reaction to peanut proteins. Peanut allergy symptoms can range from a minor irritation, such as oral pruritus, to a life-threatening anaphylactic reaction. Allergic symptoms occur from within minutes to a few hours upon ingestion of even trace quantities of peanut and frequently multiple organs are involved, including cutaneous, cardiovascular, gastrointestinal and respiratory systems. Symptoms range from a relatively mild urticarial rash, vomiting, diarrhea, wheezing, and dyspnea, to severe throat angioedema, cardiovascular collapse or fulminant anaphylaxis Allergy to peanuts (Arachis hypogea) is a serious public health problem that is estimated to affect between 1.0 and 2.0% of the adult population and between 1.0 and 3.0% of children in developed countries. Over the last few decades, an increase in the prevalence of peanut allergy amongst children and adolescents in the US has been observed, with an increase from 0.6% in 1997 to 2.1% in 2007. In approximately 70% of children with peanut allergy the first allergic reactions occur before the age of 2 years and peanut allergy reactions rarely resolve with time. The current management of peanut allergy consists of avoidance of peanut allergens along with immediate access to rescue medication, requiring a profound lifelong change in dietary habits and, in more severe disease cases, at all times carrying of an epinephrine auto-injector is necessary.
About HAL Allergy
HAL Allergy Group is active in the field of biopharmaceuticals and is located at the Bio Science Park in Leiden, The Netherlands. Our core business is the development and manufacturing of therapies and diagnostics for allergic diseases. In addition, we offer contract manufacturing services focusing on the production of biopharmaceutical products for (pre-) clinical studies. With offices in major European countries, HAL Allergy is one of the European top players in the allergy immunotherapy business. Established in 1959 HAL Allergy has long experience in developing, producing and selling allergy therapies with an immuno-modulatory effect causing a reduction in symptoms and long-term disease suppression. The allergy therapies are used against common allergies such as hay fever, house dust mites allergy and allergic reactions towards wasp or bee stings. More information is available on: http://www.hal-allergy.com
The main shareholder of HAL Allergy is Droege International Group AG, which is an independent Advisory and Investment Company, based in Düsseldorf, Germany.
Contact HAL Allergy
Group Monique Lutgens
Manager Corporate Communications
Tel. + 31 (0)88 1959010